• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Ibex Launches Breast Cancer Biomarker Diagnostic Platform

by Fred Pennic 09/08/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Ibex Medical Analytics Raises $55M to Drive AI for Cancer Diagnosis Adoption Globally

What You Should Know:

  • Ibex Medical Analytics launches Galen Breast HER2™, a novel breast cancer AI-powered biomarker scoring solution developed in collaboration with AstraZeneca and Daiichi Sankyo, to support improved patient outcomes.
  • Galen Breast HER2 is an AI-powered biomarker scoring solution to aid pathologists with reproductible HER2 assessment for breast cancer. The platform allows clinicians to rapidly and accurately identify patients with HER2-low who would benefit from targeted therapies, such as AstraZeneca’s recently approved Enhertu, connecting patients with targeted treatment to support improved patient outcomes.

HER2 Proteins Background

HER2, one of the proteins responsible for division and proliferation of breast cancer cells, is expressed in many breast tumors and its accurate assessment is critical for identifying patients who are likely to benefit from HER2-directed therapies. Traditionally, pathologists evaluate HER2 in tumor samples visually, which may result in varied interpretations as scoring is semi-quantitative and thus somewhat subjective. 

The recent emergence of antibody-drug conjugates specifically targeting HER2, which are also effective against HER2-low tumors, meant that a new segment of HER2 expression became clinically actionable. Pathologists now need to be able to evaluate and identify lower levels of HER2 expression, despite limited experience in evaluating those lower cut-offs. AI-powered tools may help pathologists with accurate, rapid, and reproducible interpretation of HER2 protein expression, particularly HER2 low, further supporting oncologists in identifying effective therapies for their patients.

Supporting Improved Biomarker Scoring in Breast Cancer Patients

Galen Breast HER2 was developed and validated by Ibex in collaboration with AstraZeneca and Daiichi Sankyo. A multi-reader validation study compared the HER2 scoring performance of pathologists and demonstrated that pathologists supported by AI showed higher consistency and accuracy for HER2 scoring, particularly on the lower levels of HER2 expression, compared to pathologists who did not use AI3. An early evidence program to generate data on the accuracy and efficiency of Galen Breast HER2 in clinical practice is now ongoing across 15 cancer centers and laboratories in the United States, Canada, Europe, the UK and Brazil. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Breast Cancer

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Nearly Half Of Consumers Report Their Healing has Been Directly Impacted by Difficulty Paying Medical Bills

Consumers Cite Healthcare Affordability as Biggest Concern to Paying Medical Bills

Mayo Clinic, GE HealthCare, Partner on Medical Imaging and Theranostics Innovation

Roundups: 16 Recent Strategic Digital Health Partnerships

How Telehealth Can Combat Clinician Burnout

How Telehealth Can Combat Clinician Burnout

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Debunking Myths About Virtual Care to Drive Health Equity

Debunking 3 Myths About Virtual Care to Drive Health Equity

Provider AI Strategy Moves From The IT Dept. To The C-Suite

Notable Launches ChatGPT-Like Assistant for Patients

Notable Launches ChatGPT-Like Assistant for Patients

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

M&A: PE Firm Acquires NextGen Healthcare EHR for $1.8B

M&A: NextGen Healthcare EHR Acquired by PE Firm for $1.8B

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |